Danaher Corporation (NYSE:DHR) Receives Average Rating of “Moderate Buy” from Analysts

Posted by Sarita Garza on Jun 14th, 2026

Danaher Corporation (NYSE:DHR – Get Free Report) has been given an average rating of “Moderate Buy” by the twenty-five analysts that are currently covering the firm, MarketBeat reports. Five research analysts have rated the stock with a hold recommendation, nineteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $233.6087.

Several research firms recently commented on DHR. HSBC decreased their target price on Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. TD Cowen decreased their target price on Danaher from $245.00 to $240.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Citigroup started coverage on Danaher in a research note on Tuesday, May 26th. They set a “buy” rating and a $230.00 target price for the company. Wolfe Research cut Danaher from an “outperform” rating to a “peer perform” rating in a research note on Monday, June 1st. Finally, DZ Bank started coverage on Danaher in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 price objective for the company.

View Our Latest Stock Analysis on Danaher

Danaher Trading Down 0.5%

NYSE DHR opened at $179.95 on Friday. The business has a 50 day simple moving average of $180.93 and a 200 day simple moving average of $204.78. Danaher has a one year low of $160.93 and a one year high of $242.80. The stock has a market capitalization of $127.37 billion, a P/E ratio of 34.81, a P/E/G ratio of 2.40 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.87 and a quick ratio of 1.52.

Danaher (NYSE:DHR – Get Free Report) last released its earnings results on Monday, April 20th. The conglomerate reported $2.06 EPS for the quarter, topping the consensus estimate of $1.94 by $0.12. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The business had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same quarter last year, the firm posted $1.88 earnings per share. The firm’s revenue was up 3.7% on a year-over-year basis. Research analysts expect that Danaher will post 8.45 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Friday, June 26th. Danaher’s dividend payout ratio (DPR) is 30.95%.

Key Danaher News

Here are the key news stories impacting Danaher this week:

Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

Institutional Investors Weigh In On Danaher

A number of hedge funds have recently added to or reduced their stakes in DHR. Norges Bank acquired a new stake in Danaher in the fourth quarter valued at approximately $2,177,106,000. Viking Global Investors LP grew its stake in Danaher by 543.9% in the second quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock valued at $574,351,000 after acquiring an additional 2,455,994 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of Danaher by 104.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,333,056 shares of the conglomerate’s stock valued at $991,923,000 after buying an additional 2,216,789 shares during the last quarter. Generation Investment Management LLP boosted its position in shares of Danaher by 34.0% during the third quarter. Generation Investment Management LLP now owns 6,654,666 shares of the conglomerate’s stock valued at $1,319,354,000 after buying an additional 1,689,020 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in shares of Danaher by 11.2% during the fourth quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock valued at $3,451,380,000 after buying an additional 1,517,904 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Company Profile

(Get Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.